Oncology Mice Models Market Expected to Reach USD 696.4 Billion by 2032 | Persistence Market Research Analysis

Oncology Mice Models Market Overview and Key Growth Drivers

The global oncology mice models market is projected to grow significantly, with an estimated market value of USD 390.3 million in 2022, and an anticipated CAGR of 6% through 2032. As of 2021, the market size was approximately USD 370.9 million, and it is expected to expand further, reaching a projected value of USD 696.4 million by 2032. The market's key growth drivers include the increasing demand for advanced cancer therapies, the growing adoption of immuno-oncology treatments, and the rising need for personalized medicine in oncology. Among the various segments, syngeneic tumor mice models are expected to maintain their dominance, holding a market share of over 50%. This segment's success is attributed to their ability to replicate the tumor microenvironment of various cancers, making them ideal for studying cancer immunotherapies and other treatment modalities.

North America is anticipated to remain the leading region for oncology mice models, driven by its strong pharmaceutical and biotechnology sectors, high research and development (R&D) spending, and the presence of top oncology research institutions. Additionally, the growing number of clinical trials focused on immunotherapy, targeted therapies, and personalized medicine has further propelled the region's dominance in this market. Europe and Asia-Pacific are also emerging as key players, with expanding healthcare infrastructure and increasing investment in oncology research.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/33046

Key Highlights from the Report

✦ The global oncology mice models market is projected to grow at a 6% CAGR from 2022 to 2032.
✦ Syngeneic tumor mice models are expected to hold over 50% of the market share by 2032.
✦ North America is expected to dominate the global oncology mice models market throughout the forecast period.
✦ The rising adoption of immuno-oncology therapies is a significant growth driver for the market.
✦ The increasing number of preclinical trials using humanized mice models is boosting market demand.
✦ The market value is expected to grow from USD 390.3 million in 2022 to USD 696.4 million by 2032.

Market Segmentation

The oncology mice models market is primarily segmented based on the type of product and the intended end-users. Product type is one of the most crucial categories, with syngeneic models, xenografts, and genetically engineered mouse models (GEMMs) representing the main subsegments. Among these, syngeneic tumor models are the most widely used due to their affordability, easy manipulation, and ability to simulate tumor growth in a genetically similar host.

On the other hand, end-users in the market include pharmaceutical companies, contract research organizations (CROs), academic research institutions, and biotechnology companies. Pharmaceutical companies are the largest end-users, relying heavily on these models to test the efficacy of new cancer drugs before advancing to clinical trials. CROs also play a vital role in the market by offering preclinical services to pharmaceutical companies, especially as drug development timelines grow shorter and the demand for cost-effective testing increases.

The increasing focus on personalized cancer treatments has driven a demand for humanized mice models, which are engineered to closely mimic human immune systems, making them ideal for studying immune-oncology therapies and cancer vaccines. Furthermore, the advancement of immuno-oncology drugs is stimulating the use of xenograft mouse models, which enable the testing of human tumor tissues in a live organism.

Regional Insights

Regionally, North America is expected to retain its dominance in the oncology mice models market due to the concentration of major pharmaceutical companies, a robust healthcare infrastructure, and the presence of leading oncology research centers. The United States, in particular, benefits from a substantial R&D budget, coupled with a growing emphasis on immuno-oncology therapies, driving demand for preclinical oncology models.

Europe follows closely, with a strong emphasis on scientific research and clinical trials. Countries such as Germany, France, and the United Kingdom are expected to contribute significantly to market growth, supported by the increasing demand for novel treatment options in oncology. The region is also experiencing rapid advancements in genetically modified mice models, which are critical in cancer research.

Asia-Pacific represents a burgeoning market for oncology mice models, spurred by increasing investment in healthcare infrastructure, growing demand for high-quality research models, and the expansion of biopharmaceuticals in countries like China, Japan, and India. Additionally, the growing adoption of immuno-oncology treatments in the region is expected to boost the market for preclinical models. The relatively low cost of research in these emerging economies presents a compelling opportunity for market players looking to expand their reach.

Market Drivers

The primary driver for growth in the oncology mice models market is the increasing focus on immuno-oncology treatments. Immuno-oncology (IO) therapies, which harness the body's immune system to fight cancer, have revolutionized cancer treatment in recent years. As more and more cancer therapies incorporate immune checkpoint inhibitors (like PD-1/PD-L1 inhibitors) and other IO-based treatments, the need for preclinical models to study these therapies is growing exponentially. Mice models, particularly syngeneic and xenograft models, are critical in providing insights into how the human immune system reacts to new drugs before clinical trials begin.

Another key factor driving market growth is the rising prevalence of cancer globally. With cancer rates continuing to climb, there is an urgent need for novel treatments. This has spurred extensive R&D activities aimed at developing more effective, personalized cancer therapies, further boosting the demand for oncology mice models in preclinical and clinical studies.

Market Restraints

Despite the growth potential, the oncology mice models market faces several challenges. One of the main restraints is the ethical concerns surrounding animal testing. As public scrutiny of animal research grows, there are increasing calls for alternatives to animal models, which could hinder market growth. While advancements in 3D cell cultures and organ-on-a-chip technologies are emerging, these alternatives have not yet fully replicated the complexities of human oncology.

Another challenge is the high cost of developing and maintaining specialized mice models, particularly humanized mice that require genetic modification. The development of these models is a time-consuming and expensive process, limiting their widespread adoption in smaller research institutions and organizations with budget constraints. Moreover, the standardization of models remains an issue, as variations in the genetic background of the mice can lead to inconsistencies in experimental results.

Market Opportunities

The oncology mice models market presents a wealth of opportunities for companies willing to innovate and adapt to changing needs. One significant opportunity lies in the advancement of humanized mice models. These models are crucial for studying immune responses to new cancer treatments, particularly immuno-oncology drugs, and offer an opportunity for growth as the industry moves toward more personalized cancer therapies.

Additionally, the growing demand for preclinical testing in emerging markets like Asia-Pacific presents a lucrative opportunity for oncology mice model suppliers. As pharmaceutical companies expand their R&D activities in these regions, there is a rising demand for high-quality preclinical models to support clinical trial data.

Reasons to Buy the Report
✔ Comprehensive market analysis and forecast for the oncology mice models industry from 2022 to 2032.
✔ In-depth insights into market segmentation based on product type, end-user, and regional trends.
✔ Detailed analysis of key drivers, restraints, and opportunities in the oncology mice models market.
✔ Competitive landscape featuring key players and their recent developments.
✔ Strategic recommendations for businesses looking to enter or expand within the oncology mice models market.

Company Insights

• Envigo
• Charles River Laboratories
• JAX
• Taconic Biosciences
• Crown Bioscience
• Horizon Discovery

Recent Developments:

1. Charles River Laboratories recently expanded its oncology mice models portfolio with the introduction of novel syngeneic and xenograft models for immuno-oncology research.

2. Envigo launched an advanced line of genetically modified mouse models tailored for preclinical cancer research, focusing on immunotherapy and personalized medicine.

Conclusion

The oncology mice models market is poised for steady growth, driven by the increasing demand for innovative cancer therapies, particularly immuno-oncology treatments. As research into personalized medicine accelerates, the need for advanced preclinical models to study cancer therapies will only intensify. While ethical concerns and high costs remain challenges, the development of humanized mice models and the expanding opportunities in emerging markets provide significant growth potential. The coming decade promises to be an exciting time for oncology mice model suppliers and pharmaceutical companies, as they continue to make strides in the fight against cancer.

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

This release was published on openPR.